Sodium Hyaluronate Injection Market Expands Amid Rising Osteoarthritis Prevalence
Global Sodium Hyaluronate Injection Market Expands Amid Rising Osteoarthritis Prevalence
November 10, 2025 – The global market for Sodium Hyaluronate (HA) Injections for Osteoarthritis (OA) pain management is positioned for steady expansion, fueled by the accelerating global prevalence of OA and the increasing demand for minimally invasive treatment options. The market size is projected to be between $250 and $500 million USD in 2025, with a projected Compound Annual Growth Rate (CAGR) of 4.5% to 8.5% through 2030.
Sodium Hyaluronate injections, also known as viscosupplementation, are a non-surgical treatment administered directly into the joint to supplement the naturally occurring hyaluronic acid in synovial fluid, aiming to restore lubrication and shock absorption. This procedure is primarily used to manage pain, stiffness, and swelling associated with OA, particularly in the knee.
Market Drivers: Addressing a Global Epidemic
The market growth is fundamentally driven by the enormous and growing patient pool suffering from OA globally:
-
Global Prevalence: In 2019, approximately 528 million people worldwide were living with OA, marking a 113% increase since 1990.
-
Aging Population: About 73% of people with OA are older than 55 years, and the knee is the most frequently affected joint (365 million people globally).
-
U.S. Impact: Over 32.5 million adults in the U.S. are affected by OA, with the lifetime risk of developing symptomatic knee OA estimated at 45%.
These statistics underscore the persistent clinical need for non-surgical interventions, as joint replacement surgery remains a last resort.
Segmentation and Competitive Landscape
The market is segmented by the dosing regimen, reflecting efforts to improve patient convenience and compliance:
| Segmentation Type | Description | Key Trend |
| Single-injection | Requires only one office visit per treatment course. | Growing in popularity due to greater patient convenience and reduced logistical burden. |
| Multi-injection | Requires two to five injections over several weeks. | Traditional regimen, still preferred for certain formulations and patient profiles. |
Key Market Players
Leading players in the Sodium Hyaluronate Injection market include established medical device and pharmaceutical companies, as well as specialized biotech firms:
-
Zimmer Biomet
-
Sanofi
-
Seikagaku
-
Anika Therapeutics
-
Bioventus Inc
-
Channel-Markers Medical LLC
-
Ferring Pharmaceuticals
-
LG Chem
-
Bloomage Biotech
-
Shanghai Haohai Biological Technology Co. Ltd.
-
SciVision Biotech Inc.
Market activity in 2025 demonstrated strategic shifts in the competitive landscape:
-
Divestiture: On July 31, 2025, Avanos Medical Inc. divested its Hyaluronic Acid product line to Channel-Markers Medical, LLC (CMM), signaling a focused acquisition of HA viscosupplementation assets by a specialized entity.
Non-HA Treatment Alternatives Driving Innovation
The market also faces competition and innovation from non-HA injectable treatments and novel technologies, which aim to offer improved efficacy and duration of relief:
-
Extended-Release Steroids: Pacira Pharmaceuticals Inc.'s ZILRETTA (triamcinolone acetonide extended-release injectable suspension) offers a long-acting intra-articular corticosteroid for knee OA pain management.
-
Ablation/Drug-Free: iovera° is a drug-free pain control device that uses precise, controlled doses of cold temperature to block nerve signals.
-
Gene Therapy: The development of PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform, indicates a long-term shift toward treatments potentially capable of modifying the disease course itself.
The future of OA pain management is rapidly evolving, with HA injections continuing to play a critical role as a foundational, minimally invasive option, while facing increasing innovation from extended-release and regenerative therapies.